A Review of the Clinical Implications of Breast Cancer Biology
Keywords:
Estrogen receptor, progesterone receptor, biological markers, breast cancer, human epidermal growth factor receptor-2Abstract
Background: Histologically similar tumors may have different prognoses and responses to treatment. These differences are due to molecular differences. Hence, in this review, the biological interaction of breast cancer in several different areas is discussed. In addition, the performance and clinical application of the most widely-recognized biomarkers, metastasis, and recurrences from a biological perspective and current global advances in these areas are addressed.
Objective: This review provides the performance and clinical application of the most widely-recognized biomarkers, metastasis, and recurrences from the biological perspective and current global advances in these areas.
Methods: PubMed, Scopus, and Google Scholar were searched comprehensively with combinations of the following keywords: “breast cancer,” “biological markers,” and “clinical.” The definition of breast cancer, diagnostic methods, biological markers, and available treatment approaches were extracted from the literature.
Results: Estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor-2 (HER-2), and Ki-67 are the most well-known biological markers that have important roles in prognosis and response to therapeutic methods. Some studies showed the response of ER-positive and PR-negative tumors to anti-estrogenic treatment to be lower than ER-positive and PR-positive tumors. Patients with high expression of HER-2 and Ki-67 had a poor prognosis. In addition, recent investigations indicated the roles of new biomarkers, such as VEGF, IGF, P53 and P21, which are associated with many factors, such as age, race, and histological features.
Conclusion: The objective of scientists, from establishing a relationship between cancer biology infrastructures with clinical manifestations, is to find new ways of prevention and progression inhibition and then possible introduction of less dangerous and better treatments to resolve this dilemma of human society.
References
Howell A, Sims AH, Ong KR, Harvie MN, Evans DGR, Clarke RB. Mechanisms of Disease: prediction
and prevention of breast cancer-cellular and molecular interactions. Nat Clin Pract Oncol. 2005; 2(12):
-46. doi: 10.1038/ncponc0361. PMID: 16341119.
Varangot M, Barrios E, Sóñora C, Aizen B, Pressa C, Estrugo R, et al. Clinical evaluation of a panel of
mRNA markers in the detection of disseminated tumor cells in patients with operable breast cancer. Oncol
rep. 2005; 14(2): 537-45. doi: 10.3892/or.14.2.537. PMID: 16012742.
Gerrero MR, Weber BL. Recent advances in breast cancer biology. Curr opin oncol. 2001; 13(6): 415-9.
doi: 10.1097/00001622-200111000-00001. PMID: 12409647.
Steel C, Smyth E. Molecular pathology of breast cancer and its impact on clinical practice. Schweiz Med
Wochenschr. 1999; 129(46): 1749-57. PMID: 10603648.
Chassevent A, Jourdan M-L, Romain S, Descotes F, Colonna M, Martin P-M, et al. S-Phase Fraction and
DNA Ploidy in 633 T1T2 breast cancers a standardized flow cytometric study. Clin Cancer Res. 2001;
(4): 909-17. PMID: 11309341.
Stratton MR, Rahman N. The emerging landscape of breast cancer susceptibility. Nat genet. 2008; 40(1):
-22. doi: 10.1038/ng.2007.53. PMID: 18163131.
Olah E. [The first 20 years of the Department of Molecular Genetics of the National Institute of Oncology
(NIO)]. Magyar onkologia. 2006; 51(2): 89-94.
Gerger A, Langsenlehner U, Renner W, Weitzer W, Eder T, Yazdani-Biuki B, et al. A multigenic approach
to predict breast cancer risk. Breast Cancer Res Treat. 2007; 104(2): 159-64. doi: 10.1007/s10549-006- 9408-4. PMID: 17058024.
Raza A, Preisler H, Lampkin B, Yousuf N, Tucker C, Peters N, et al. Biological significance of cell cycle
kinetics in 128 standard risk newly diagnosed patients with acute myelocytic leukaemia. Br J Haematol.
; 79(1): 33-9. doi: 10.1111/j.1365-2141.1991.tb08003.x. PMID: 1911386.
Ingvarsson S, editor Molecular genetics of breast cancer progression. Seminars in cancer biology; 1999:
Elsevier.
Mirmalek SA, Hajilou M, Salimi Tabatabaee SA, Parsa Y, Yadollah Damavandi S, Parsa T. Prevalence of
HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients.
Int J Breast Cancer. 2014; 2014.
Børresen A-L, Andersen TI, Garber J, Barbier-Piraux N, Thorlacius S, Eyfjörd J, et al. Screening for germ
line TP53 mutations in breast cancer patients. Cancer res. 1992; 52(11): 3234-6. PMID: 1591732.
Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome
in twenty-four kindreds. Cancer res. 1988; 48(18): 5358-62. PMID: 3409256
Gralow JR. Breast cancer 2004: Progress and promise on the clinical front. Phys Med. 2006; 21: 2. doi:
1016/S1120-1797(06)80011-6. PMID: 17645981.
Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, et al. Linkage of early-onset familial
breast cancer to chromosome 17q21. Science. 1990; 250(4988): 1684-9. doi: 10.1126/science.2270482.
PMID: 2270482.
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, et al. A strong candidate for
the breast and ovarian cancer susceptibility gene BRCA1. Science. 1994; 266(5182): 66-71. doi:
1126/science.7545954. PMID: 7545954.
Wooster R, Neuhausen SL, Mangion J, Quirk Y, Ford D, Collins N, et al. Localization of a breast cancer
susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994; 265(5181): 2088-90. doi:
1126/science.8091231. PMID: 8091231.
Berry DA, Parmigiani G, Sanchez J, Schildkraut J, Winer E. Probability of carrying a mutation of breast- ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst. 1997; 89(3): 227-37. doi:
1093/jnci/89.3.227. PMID: 9017003.
Burke W, Daly M, Garber J, Botkin J, Kahn MJE, Lynch P, et al. Recommendations for follow-up care of
individuals with an inherited predisposition to cancer: II. BRCA1 and BRCA2. Jama. 1997; 277(12): 997- 1003. doi: 10.1001/jama.1997.03540360065034. PMID: 9091675.
Couch FJ, DeShano ML, Blackwood MA, Calzone K, Stopfer J, Campeau L, et al. BRCA1 mutations in
women attending clinics that evaluate the risk of breast cancer. N Engl J Med. 1997; 336(20): 1409-15. doi:
1056/NEJM199705153362002. PMID: 9145677.
Fuckar D, Dekanic A, Stifter S, Mustac E, Krstulja M, Dobrila F, et al. VEGF expression is associated with
negative estrogen receptor status in patients with breast cancer. Int J Surg Pathol. 2006; 14(1): 49-55. doi:
1177/106689690601400109. PMID: 16501835.
Webster LR, Bilous AM, Willis L, Byth K, Burgemeister FC, Salisbury EL, et al. Histopathologic
indicators of breast cancer biology. Cancer Res. 2004; 64(7 Supplement): 1214-5.
Dean M. Cancer stem cells: redefining the paradigm of cancer treatment strategies. Mol Interv. 2006; 6(3):
doi: 10.1124/mi.6.3.5. PMID: 16809475.
Elston C. Classification and grading of invasive breast carcinoma. Verh Dtsch Ges Pathol. 2005; 89: 35-44.
PMID: 18035670.
Van Laere S, Van der Auwera I, Van den Eynden G, Van Hummelen P, Van Dam P, Van Marck E, et al.
Distinct molecular phenotype of inflammatory breast cancer compared to non-inflammatory breast cancer
using Affymetrix-based genome-wide gene-expression analysis. Br J Cancer. 2007; 97(8): 1165-74. doi:
1038/sj.bjc.6603967. PMID: 17848951, PMCID: PMC2360452.
Cabioglu N, Gong Y, Islam R, Broglio K, Sneige N, Sahin A, et al. Expression of growth factor and
chemokine receptors: new insights in the biology of inflammatory breast cancer. Ann oncol. 2007; 18(6):
-9. doi: 10.1093/annonc/mdm060. PMID: 17351259.
Polyak K, Hu M. Do myoepithelial cells hold the key for breast tumor progression? J Mammary Gland Biol
Neoplasia. 2005; 10(3): 231-47. doi: 10.1007/s10911-005-9584-6. PMID: 16807803.
Surowiak P, Suchocki S, GyĂśrffy B, Gansukh T, Wojnar A, Maciejczyk A, et al. Stromal myofibroblasts
in breast cancer: relations between their occurrence, tumor grade and expression of some tumour markers.
Folia Histochem Cytobiol. 2006; 44(2): 111-0. PMID: 16805136.
Balducci L, Aapro M. Epidemiology of cancer and aging. Cancer Treat Res. 2005; 124: 1-15. doi:
1007/0-387-23962-6_1. PMID: 15839188.
Ivković-Kapicl T, Knežević-Ušaj S, Panjković M, Ninčić D, Mastilović K. The influence of aging on
pathologic and immunobiologic parameters of invasive ductal breast carcinoma. Vojnosanit Pregl. 2006;
(11): 921-7. doi: 10.2298/VSP0611921I. PMID: 17144425.
Benz C, Thor A, Eppenberger-Castori S, Eppenberger U, Moore 3rd D. Understanding the age dependency
of breast cancer biomarkers. Adv Gerontol . 2003; 11: 117-20. PMID: 12820531.
Klauber-DeMore N. Tumor biology of breast cancer in young women. Breast dis. 2006; 23(2005): 9-15.
PMID: 16823162.
Balducci L. Management of cancer in the elderly. Oncology. 2006; 20(2): 135-43. PMID: 16562648.
Benz CC. Impact of aging on the biology of breast cancer. Crit Rev Oncol Hematol. 2008; 66(1): 65-74.
doi: 10.1016/j.critrevonc.2007.09.001. PMID: 17949989, PMCID: PMC2626623.
Zabicki K, Colbert JA, Dominguez FJ, Gadd MA, Hughes KS, Jones JL, et al. Breast cancer diagnosis in
women≤ 40 versus 50 to 60 years: Increasing size and stage disparity compared with older women over
time. Ann Surg Oncol. 2006; 13(8): 1072-7. doi: 10.1245/ASO.2006.03.055. PMID: 16865599
Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis
correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene
expression. J Clin Oncol. 2008; 26(20): 3324-30. doi: 10.1200/JCO.2007.14.2471. PMID: 18612148.
Masi CM, Olopade OI. Racial and ethnic disparities in breast cancer: a multilevel perspective. Med Clin
North Am. 2005; 89(4): 753-70. doi: 10.1016/j.mcna.2005.02.004. PMID: 15925648.
Ikpatt O, Kuopio T, Collan Y. Proliferation in African breast cancer: biology and prognostication in
Nigerian breast cancer material. Mod pathol. 2002; 15(8): 783-9. doi:
1097/01.MP.0000021764.03552.BD. PMID: 12181262.
Amend K, Hicks D, Ambrosone CB. Breast cancer in African-American women: differences in tumor
biology from European-American women. Cancer Res. 2006; 66(17): 8327-30. doi: 10.1158/0008- 5472.CAN-06-1927. PMID: 16951137.
Rose DP, Royak-Schaler R. Tumor biology and prognosis in black breast cancer patients: a review. Cancer
Detect Prev. 2000; 25(1): 16-31. PMID: 11270418.
Esteva FJ, Hortobagyi GN. Prognostic molecular markers in early breast cancer. Breast cancer res. 2004;
(3): 109-18. doi: 10.1186/bcr777. PMID: 15084231, PMCID: PMC400674.
Lønning P. Breast cancer prognostication and prediction: are we making progress? Ann Oncol. 2007;
(suppl 8): viii3-viii7.
Shao W, Brown M. Advances in estrogen receptor biology: prospects for improvements in targeted breast
cancer therapy. Breast Cancer Res. 2004; 6(1): 39-52. doi: 10.1186/bcr742. PMID: 14680484, PMCID:
PMC314456.
Huang J, Li X, Hilf R, Bambara RA, Muyan M. Molecular basis of therapeutic strategies for breast cancer.
Curr Drug Targets Immune Endocr Metabol Disord. 2005; 5(4): 379-96. doi:
2174/156800805774912944. PMID: 16375692.
Markey CM, Coombs MA, Sonnenschein C, Soto AM. Mammalian development in a changing
environment: exposure to endocrine disruptors reveals the developmental plasticity of steroid‐hormone
target organs. Evol dev. 2003; 5(1): 67-75. doi: 10.1046/j.1525-142X.2003.03011.x. PMID: 12492412.
Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and
progression. Endocr Relat Cancer. 2007; 14(2): 189-206. doi: 10.1677/ERC-06-0068. PMID: 17639037.
Foidart J-M, Colin C, Denoo X, Desreux J, Béliard A, Fournier S, et al. Estradiol and progesterone regulate
the proliferation of human breast epithelial cells. Fertil Steril. 1998; 69(5): 963-9. doi: 10.1016/S0015- 0282(98)00042-9.
Colditz GA. Relationship between estrogen levels, use of hormone replacement therapy, and breast cancer.
J Natl Cancer Inst. 1998; 90(11): 814-23. doi: 10.1093/jnci/90.11.814. PMID: 9625169. 49) Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. J Coll
Physicians Surg Pak. 2005; 15(4): 230-3. PMID: 15857597.
Lanari C, Molinolo AA. Progesterone receptors-animal models and cell signaling in breast cancer: Diverse
activation pathways for the progesterone receptor-possible implications for breast biology and cancer.
Breast Cancer Res. 2002; 4(6): 240. doi: 10.1186/bcr539. PMID: 12473170, PMCID: PMC137940.
Tonini G, Schiavon G, Fratto ME, Vincenzi B, Santini D. Hormono-biological therapy in metastatic breast
cancer: preclinical evidence, clinical studies and future directions. 2008.
Massarweh S, Schiff R. Resistance to endocrine therapy in breast cancer: exploiting estrogen
receptor/growth factor signaling crosstalk. Endocr Relat Cancer. 2006; 13(Supplement 1): S15-S24. doi:
1677/erc.1.01273. PMID: 17259554.
Gruvberger-Saal SK, Bendahl PO, Saal LH, Laakso M, Hegardt C, Edén P, et al. Estrogen receptor β
expression is associated with tamoxifen response in ERα-negative breast carcinoma. Clin Cancer Res.
; 13(7): 1987-94. doi: 10.1158/1078-0432.CCR-06-1823. PMID: 17404078.
Jacobsen BM, Schittone SA, Richer JK, Horwitz KB. Progesterone-independent effects of human
progesterone receptors (PRs) in estrogen receptor-positive breast cancer: PR isoform-specific gene
regulation and tumor biology. Mol Endocrinol. 2005; 19(3): 574-87. doi: 10.1210/me.2004-0287. PMID:
Harvey P, Everett D, Springall C. Hyperprolactinaemia as an adverse effect in regulatory and clinical
toxicology: role in breast and prostate cancer. Hum Exp Toxicol. 2006; 25(7): 395-404. doi:
1191/0960327106ht643oa. PMID: 16898168.
Mirmalek SA, Elhamkani F, Tabatabaee SAS, Mahmoodzadeh H, Parsa Y, Yadollah-Damavandi S, et al.
Introduction of HER-2 and a Short Review on Its Role in Prognosis and Treatment of Breast Cancer. Galen
Medical Journal. 2014; 3(3): 132-44.
Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology. 2001; 61(Suppl. 2): 1-13. doi:
1159/000055396. PMID: 11694782.
Ibrahim YH, Yee D. Insulin-like growth factor-I and breast cancer therapy. Clin cancer res. 2005; 11(2):
s-50s. PMID: 15701891.
Frasca F, Pandini G, Vigneri R, Goldfine ID. Insulin and hybrid insulin/IGF receptors are major regulators
of breast cancer cells. Breast dis. 2002; 17: 73-89. PMID: 15687679.
Wincewicz A, Koda M, Sulkowska M, Kanczuga-Koda L, Wincewicz D, Sulkowski S. STAT3 and
hypoxia induced proteins--HIF-1alpha, EPO and EPOR in relation with Bax and Bcl-xL in nodal
metastases of ductal breast cancers. Folia Histochem Cytobiol. 2010; 47(3): 425-4. doi: 10.2478/v10042- 009-0099-7. PMID: 20164027.
Hyder S. Sex-steroid regulation of vascular endothelial growth factor in breast cancer. Endocr Relat
Cancer. 2006; 13(3): 667-87. doi: 10.1677/erc.1.00931. PMID: 16954424.
Kristiansen G, Winzer K-J, Mayordomo E, Bellach J, Schlüns K, Denkert C, et al. CD24 expression is a
new prognostic marker in breast cancer. Clini Cancer Res. 2003; 9(13): 4906-13. PMID: 14581365.
Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, et al. The novel p21
polymorphism p21G251A is associated with locally advanced breast cancer. Clin cancer res. 2006; 12(20):
-4. doi: 10.1158/1078-0432.CCR-05-2822. PMID: 17062672.
Joensuu K, Heikkilä P, Andersson LC. Tumor dormancy: elevated expression of stanniocalcins in late
relapsing breast cancer. Cancer lett. 2008; 265(1): 76-83. doi: 10.1016/j.canlet.2008.02.022. PMID:
Li B, Zhu Z, Wang J, Hou J, Zhao J, Zhang P, et al. [Expression correlation of Ki67 to P53, VEGF, and C- erbB-2 genes in breast cancer and their clinical significances]. Ai zheng. 2004; 23(10): 1176-9. PMID:
Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A'Hern R, et al. Prognostic value of Ki67 expression
after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99(2):
-70. doi: 10.1093/jnci/djk020. PMID: 17228000.
Harvey HA, Cream LV. Biology of bone metastases: causes and consequences. Clin breast cancer. 2007; 7:
S7-S13. doi: 10.3816/CBC.2007.s.001. PMID: 17683652.
Akhtari M, Mansuri J, Newman KA, Guise TM, Seth P. Biology of breast cancer bone metastasis. Cancer
Biol Ther. 2008; 7(1): 3-9. doi: 10.4161/cbt.7.1.5163. PMID: 18059174.
Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, et al. Circulating tumor cells, disease
progression, and survival in metastatic breast cancer. N Engl J Med. 2004; 351(8): 781-91. doi:
1056/NEJMoa040766. PMID: 15317891.
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
